Bobbie J. Rimel

TL;DR: Among patients with platinum-sensitive, recurrent ovarian cancer, the median duration of progression-free survival was significantly longer amongThose receiving niraparib than among those receiving placebo, regardless of the presence or absence of gBRCA mutations or HRD status, with moderate bone marrow toxicity.

TL;DR: Cediranib plus olaparib seems to improve PFS in women with recurrent platinum-sensitive high-grade serous or endometrioid ovarian cancer, and warrants study in a phase 3 trial.

TL;DR: The data support expansion of the treatment indication for poly(ADP-ribose) polymerase inhibitors to include patients with HRD-positive ovarian cancer beyond those with BRCA mutations and clinically relevant activity of niraparib among women with heavily pretreated ovarian cancer.

TL;DR: Benefit appears to be strongest in a distinct population of patients with BRCA mutations or other defects in homologous recombination repair, and combination therapies, which include anti-angiogenesis agents and immunotherapy, show promise as a strategy to broaden efficacy for unselected patients.

TL;DR: Combination cediranib/olaparib significantly extends PFS compared with olaparIB alone in relapsed platinum-sensitive ovarian cancer, and subset analyses suggest this margin of benefit is driven by PFS prolongation in patients without gBRCAm.